Dr. David Hyman is the Chief Medical Officer for Eli Lilly and Company. In this role, David works closely with the Chief Scientific Officer, development leaders across therapeutic areas, and business development to advance Lilly’s portfolio of medicines. David also directly leads development in the oncology group, Loxo@Lilly. Previously, David served as Chief of the Early Drug Development service at Memorial Sloan Kettering. He is credited with playing a pivotal role in the creation of ‘basket studies’ and was involved in the approval of several drugs. David spent the initial part of his career as a practicing academic oncologist with a research focus in targeted therapy, cancer genomics, and drug development. David received his MD from Weill Medical College and his BS degree in biology from Brown University